18th week of 2022 patent applcation highlights part 33 |
Patent application number | Title | Published |
20220135930 | FAT FRAGMENTATION DEVICE AND METHOD - The present invention provides a device for adipose tissue processing, microfragmentation and facilitation of mechanical separation of adipose derived stem cells (“ADSCs”), methods of using the device to generate a stromal vascular fraction (“SVF”) and methods of the SVF. | 2022-05-05 |
20220135931 | FLOW-THROUGH PARAMAGNETIC PARTICLE-BASED CELL SEPARATION AND PARAMAGNETIC PARTICLE REMOVAL - The present disclosure relates to systems and methods for flow-through separation of paramagnetic particle-bound cells in a cell suspension containing both bound and unbound cells as well as systems and methods for removing paramagnetic particles from paramagnetic particle-bound cells or from a cell suspension with unbound cells. It further relates to a flow-through magnetic separation/debeading module and a flow-through spinning membrane debeading module. | 2022-05-05 |
20220135932 | PHOTOBIOREACTOR FOR BLUE-GREEN ALGAE CULTIVATION - The present invention concerns the field of high-efficiency, quality-controlled production of blue-green algae for direct human consumption, for extraction of proteins, vitamins, and amino acids, and for production of organic materials loaded with the special isotope 13C. | 2022-05-05 |
20220135933 | PARALLEL AND INTERCONNECTED CELL CULTURE VESSEL SYSTEM - Embodiments relate to a unique design of a cell growth vessel stack system that provides for inter-communication of cell growth levels arranged in a parallel configuration so to facilitate environmental uniformity of the inter-connected growth surface tiers. The unique design also facilitates a fine-tuning of optimized gas and media flow to each cell growth level within the vessel stack. The unique architecture facilitates media refreshment at conveniently scheduled intervals and/or allows constant perfusion from a media reservoir that can be replenished without interrupting the cell proliferation rate. The perfusion rate, nutrient medium condition, CO2 content and osmolality can be controlled to optimize the desired cell proliferation rate, thereby improving cell quantity, quality, and viability. | 2022-05-05 |
20220135934 | METHOD FOR PRODUCING CULTURE OF LACTIC ACID BACTERIUM AND/OR BACTERIUM BELONGING TO GENUS BIFIDOBACTERIUM - By a method for producing a culture for obtaining a culture by culturing a lactic acid bacterium and/or a bacterium belonging to the genus | 2022-05-05 |
20220135935 | COMPOSITION COMPRISING LACTOBACILLUS SAKEI CVL-001 OR CULTURE LIQUID THEREOF FOR ALLEVIATING, PREVENTING, OR TREATING BONE DISEASES OR METABOLIC DISEASES - The present invention relates to a | 2022-05-05 |
20220135936 | BREVUNDIMONAS STRAIN AS ENDOSYMBIONT OF VERTICILLIUM DAHLIAE AND USE THEREOF - The present disclosure provides a | 2022-05-05 |
20220135937 | ELECTROPORATION DEVICE AND METHOD FOR PRODUCING CELLS WITH INTRODUCED FOREIGN SUBSTANCE - Provided is an electroporation device and a method for producing cells with an introduced foreign substance, with which, compared to a device that performs electroporation by causing a solution (droplet) containing a foreign substance and cells to reciprocate in oil, an operation to recover a sample after a reaction is simplified. | 2022-05-05 |
20220135938 | NUTRITION COMPOSITION - The present invention provides a means for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells. The nutrition composition according to the present invention is a nutrition composition for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells, the nutrition composition containing at least one essential amino acid selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine and histidine except valine, and optionally containing a non-essential amino acid(s). | 2022-05-05 |
20220135939 | METHODS FOR DETECTING DISEASES AND DISORDERS CHARACTERIZED BY ABERRANT RED BLOOD CELL AGGREGATION - This invention addresses accurately and rapidly diagnosing diseases, disorders, or conditions characterized by aberrant red blood cell aggregation, including infections caused by RNA viruses, particularly those caused by positive-sense, single-stranded RNA viruses, known to cause human disease. Examples of such viruses include various betacoronaviruses, including SARS-CoV, MERS-CoV, and SARS-CoV-2, that later of which causes COVID-19, a potentially fatal illness. | 2022-05-05 |
20220135940 | METHOD FOR PRODUCING KIDNEY STRUCTURE HAVING DENDRITICALLY BRANCHED COLLECTING DUCT FROM PLURIPOTENT STEM CELLS - An exemplary method can be provided for producing ureteric bud cells from pluripotent stem cells, in vitro. Further, an exemplary method can be provided for producing ureteric bud cells and Wolffian duct (WD) progenitor-like cells that are a progenitor of the ureteric bud cells. Another exemplary method can be provided for producing Wolffian duct (WD) progenitor-like cells that can comprise obtaining C-X-C chemokine receptor 4 (CXCR4) positive and KIT proto-oncogene receptor tyrosine kinase (KIT) positive cells. In addition, an exemplary method can be provided for producing ureteric-bud-like cells using WD progenitors that are CXCR4+ and KIT+, and another exemplary method can be provided for producing kidney organoids in which the ureteric-bud-like cells can be used. | 2022-05-05 |
20220135941 | COMPOSITIONS AND METHODS FOR LONG TERM CULTURE OF HEPATOCYTES - Provided are compositions for long-term maintenance of functional hepatocytes in culture, a method for improved maintenance of functional hepatocytes in vitro, and functional hepatocytes cultures according to the methods. The culture compositions include at least: one activator of adenylate cyclase, one TGFβ inhibitor, one Notch inhibitor, one Wnt inhibitor, and/or one BMP inhibitor. The combinations of compounds are added to any hepatocyte cell culture medium in an effective amount to maintain functional hepatocyte function in vitro, long term. The hepatocytes can be used for in vitro drug research and to model liver disease. | 2022-05-05 |
20220135942 | CULTURED TISSUE AND METHOD FOR PRODUCING SAME - A cultured tissue, comprising: glandular cells; glandular cavities formed from the glandular cells; and ducts formed from epithelial cells, wherein the glandular cavities and the ducts are functionally connected ex vivo. | 2022-05-05 |
20220135943 | CELL CULTURE MEDIUM AND METHOD FOR GENERATION OF EPITHELIAL ORGANOIDS FROM EPITHELIAL STEM CELLS - The present invention provides a cell culture for obtaining an epithelial organoid, the cell culture comprising i) epithelial stem cells, or tissue fragments comprising said epithelial stem cells, ii) a basal medium for animal or human cells, iii) a Bone Morphogenetic Protein (BMP) inhibitor, iv) a mitogenic growth factor selected from the group consisting of epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF) and keratinocyte growth factor (KGF), v) at least one soluble culture enhancer, wherein said at least one culture enhancer induces correct polarization of the cells in said cell culture within the developing organoid such as a laminin/entactin complex or entactin, and vi) a Wnt agonist if said epithelial stem cells, or tissue fragments comprising said epithelial stem cells are healthy cells, wherein said at least one soluble culture enhancer in said cell culture is a laminin/entactin complex in a concentration between 0.2 mg/ml and 3.4 mg/ml. A cell culture medium, an in-vitro method for obtaining an epithelial organoid, and an epithelial organoid obtained by said method are also disclosed. | 2022-05-05 |
20220135944 | METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT CANCERS AND COMPOSITIONS THEREOF - Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a novel group of cell surface receptors that recognize peptides on the surface of a target cell are provided. Also provided herein are populations of T cells produced by methods described herein and pharmaceutical compositions thereof. | 2022-05-05 |
20220135945 | GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE - Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject. | 2022-05-05 |
20220135946 | CD34+CD41DIM MEGAKARYOCYTES PROGENITORS AND USES THEREOF FOR PRODUCING PROPLATELET-BEARING MKS AND/OR PLATELETS - The invention relates to a method of producing CD34 | 2022-05-05 |
20220135947 | METHODS FOR CULTURING MESENCHYMAL STEM CELLS, PRODUCTS THEREOF, AND APPLICATIONS THEREOF - The present disclosure provides a process for obtaining an expanded primed mesenchymal stem cell population. In the process, the MSCs are cultured in the culture medium comprising a corneal stromal stem cell derived-conditioned medium to obtain the expanded population of the primed mesenchymal stem cell population along with the mesenchymal stem cell derived-conditioned medium. Also, provided is a method of culturing the MSCs in 3D culture using a spheroid-based method or a microcarrier-based method, in order to obtain the expanded primed mesenchymal stem cell population. Further, an exosome preparation obtained from the expanded primed mesenchymal stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the primed mesenchymal stem cells, or a primed mesenchymal stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof. | 2022-05-05 |
20220135948 | METHODS OF USING PDX1-POSITIVE PANCREATIC ENDODERM CELLS AND ENDOCRINE PRECURSOR CELLS - Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations. | 2022-05-05 |
20220135949 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME - The present invention relates to a method for preparing a human intestinal epithelial model. The human intestinal epithelial model, prepared by the method according to the present invention, has all characteristics of goblet cells, enteroendocrine cells, and Paneth cells, and thus can highly mimic the function of actual human intestinal cells, so that the human intestinal epithelial model can be effectively used for development of new drugs, evaluation of drug absorption and toxicity, or evaluation of engraftment of intestinal microorganisms, or as a composition for in vivo transplantation. | 2022-05-05 |
20220135950 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME - The present invention relates to a method for preparing a human intestinal epithelial model. The human intestinal epithelial model, prepared by the method according to the present invention, has all characteristics of goblet cells, enteroendocrine cells, and Paneth cells, and thus can highly mimic the function of actual human intestinal cells, so that the human intestinal epithelial model can be effectively used for development of new drugs, evaluation of drug absorption and toxicity, or evaluation of engraftment of intestinal microorganisms, or as a composition for in vivo transplantation. | 2022-05-05 |
20220135951 | RENAL TUBE ASSAY DEVICE AND METHODS OF MANUFACTURE AND USE - A renal tube assay device can include: a container having an inlet port and an outlet port; a matrix material in the container; and a lumen in the matrix material extending from the inlet port to the outlet port. The lumen can include a luminal surface with at least one low density region that has a lower density compared to another adjacent region of the matrix material that is located at least partially around the at least one low density region. The low density region can have a form of a bubble, bulge, capsule, or the like. The low density region can bulge into the lumen. A port can be adapted for receiving a pipette tip. The matrix material can include a hydrogel. The container can be located in a cell culture dish. | 2022-05-05 |
20220135952 | Culture Medium - The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids. | 2022-05-05 |
20220135953 | BIOFUNCTIONALIZED HYDROGEL FOR CELL CULTURE - Provided are biomaterials useful for cell culture, method of preparation thereof, and use thereof. The present biomaterial comprises a crosslinked hydrogel and a peptide chemically attached to the hydrogel, wherein the peptide comprises a histidine-alanine-valine (HAV) sequence. In particular, the present biomaterial may be useful for culturing neurons, brain endothelial cells, and/or glial cells, supporting the formation of synaptically connected neural networks, and growing stem cell-derived organoids that more closely resemble human organs. | 2022-05-05 |
20220135954 | NUCLEIC ACID CONSTRUCTS FOR VA RNA TRANSCRIPTION - Herein is reported a novel adenoviral VA RNA nucleic acid wherein the wild-type type 2 polymerase III promoter has been removed and an U6-snRNA promoter or an inducible promoter has been added. | 2022-05-05 |
20220135955 | Reverse Transcriptase Mutants with Increased Activity and Thermostability - The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates. | 2022-05-05 |
20220135956 | MODIFIED ENZYMES - The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides. | 2022-05-05 |
20220135957 | Methods for Promoting Extracellular Expression of Proteins in Bacillus subtilis Using a Cutinase - Disclosed is a method for promoting extracellular expression of proteins in | 2022-05-05 |
20220135958 | CLASS 2 CRISPR-CAS RNA-GUIDED ENDONUCLEASES - Provided herein are novel Class 2 Type II, Type V, type VI CRISPR-Cas RNA-guided endonucleases and systems comprising the same. Provided also are methods of making, and methods of use thereof. Exemplary methods of use include modifying target nucleic acids useful for therapeutic applications, and also include detecting targeting nucleic acids, useful for diagnostic applications. | 2022-05-05 |
20220135959 | CHIMERIC CLOTTING FACTORS - The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors. | 2022-05-05 |
20220135960 | POLYPEPTIDE TAG, HIGHLY SOLUBLE RECOMBINANT NITRILASE AND APPLICATION THEREOF IN SYNTHESIS OF PHARMACEUTICAL CHEMICALS - The present invention provides a polypeptide tag and its application in the synthesis of pharmaceutical chemicals, the recombinant nitrilase was obtained by connecting a polypeptide tag to the N-terminus of the amino acid sequence of the nitrilase; wherein amino acids at both ends of the polypeptide tag are uncharged glycine G, and the rest are a random combination of any one or more of glycine G, histidine H, glutamic acid E, aspartic acid D, lysine K and arginine R; The activity of the recombinant nitrilase in the preparation of 1-cyanocyclohexyl acetic acid is up to 3034.7 U/g dcw, the polypeptide tag significantly improves the soluble expression of nitrilase, and the whole cell catalyst hydrolyzes 1M substrate with the same concentration 30 minutes faster than the mother enzyme. The method provided by the present invention can also be used for the biocatalytic reaction of other pharmaceutical intermediates as the substrate catalyzed by the nitrilase, improving the activity of the whole cell catalyst in reaction, and also improving the solubility of other types of nitrilases and the activity of the corresponding whole cell catalysts. | 2022-05-05 |
20220135961 | Tethering Cysteine Residues Using Cyclic Disulfides - Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization. | 2022-05-05 |
20220135962 | METHODS AND MATERIALS FOR BIOLOGICAL IMMOBILIZATION IN MICROFLUIDICS - The present invention is directed to synthesizing and using fluid-insoluble material complexes that capture biologicals and remove them from samples in microscopic scale fluids, such as in droplets, wells, and micro-wells. The present invention also pertains to the option of detecting the captured biologicals, to the option of modifying the captured biologicals, and to the option of controllably releasing the captured biologicals. | 2022-05-05 |
20220135963 | TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS - Provided are methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell for deamination of an adenosine in a target RNA, deaminase-recruiting RNAs used in the RNA editing methods, compositions and kits comprising the same. | 2022-05-05 |
20220135964 | Systems and Methods to Assess RNA Stability - Systems and methods for assessing mRNA in vivo and/or in vitro stability are disclosed. Some embodiments methods obtain RNA indexed or barcoded RNA molecules which are then tested against various conditions including stability inside of cells, stability in cell lysate, and stability in solution (e.g., for storage and/or transportation). Additional embodiments describe methods to determine degradation points with single base resolution. | 2022-05-05 |
20220135965 | LIBRARIES FOR NEXT GENERATION SEQUENCING - Provided herein are compositions and methods for Next Generation Sequencing. Further provided herein are compositions and methods for uniquely labeling molecules. Further provided herein are compositions and methods for synthesizing unique molecular identifiers. | 2022-05-05 |
20220135966 | SYSTEMS AND METHODS FOR MAKING SEQUENCING LIBRARIES - This invention relates to systems and methods for making libraries of molecularly distinct polynucleotides. In particular, methods of the invention involve randomly fragmenting nucleic acids (e.g., RNA) to create fragments with cleaved ends at random cleavage locations. Preferably, methods also include reverse transcribing the fragments of RNA in the presence of molecular diversity enhancers (i.e., short random sequences), thereby creating polynucleotides with the molecular diversity enhancers copied therein. The result is a library of polynucleotides that are uniquely identifiable based on combinations of the random cleavage locations and molecular diversity enhancers. | 2022-05-05 |
20220135967 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION - The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound. | 2022-05-05 |
20220135968 | TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY - Treatments for synucleinopathy including Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB) are largely unavailable. The invention provides methods for treating, preventing, inhibiting, and reversing synucleinopathy by attenuating MSH activity, decreasing MSH expression, or by modulating MSH engagement with its receptor by utilizing antagonists. Furthermore, the inventor has provided a method for producing a synucleinopathy animal model for screening treatments and for studying synuclein disease pathology. | 2022-05-05 |
20220135969 | PLANT DNA METHYLTRANSFERASES AND USES THEREOF - An isolated polynucleotide encoding a fusion protein which comprises a DNA targeting moiety linked to a catalytic domain of a plant DNA methyltransferase 3 (DNMT3) protein is disclosed. Uses thereof are also disclosed. | 2022-05-05 |
20220135970 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA - CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein. | 2022-05-05 |
20220135971 | CORE MASTER REGULATORS OF GLIOBLASTOMA STEM CELLS - Provided methods of inhibiting a glioblastoma stem-like cell (GSC), methods of treating a subject with glioblastoma, and methods of reprogramming an astrocyte to a glioblastoma stem-like cell (GSC). | 2022-05-05 |
20220135972 | OPTIMAL PS MODIFICATION PATTERN FOR HETERONUCLEIC ACIDS - An object of the present invention is to provide a double-stranded nucleic acid complex having a reduced number of PS modifications in an antisense strand and maintaining an antisense effect. An optimal PS modification pattern for double-stranded nucleic acid complexes is disclosed. Such a nucleic acid complex comprising an antisense strand having an optimal PS modification pattern has a characteristic of having low toxicity and high bioavailability. The double-stranded nucleic acid complex comprising an antisense strand having an optimal PS modification pattern according to the present invention is useful when used as a nucleic acid drug that utilizes inhibition of expression of a specific gene (knockdown), activity that changes the function of coating or non-coding RNA for a specific gene, or activity that changes the function of RNA by inducing exon skipping during processing of pre-mRNA for a specific gene. | 2022-05-05 |
20220135973 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS - Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials. | 2022-05-05 |
20220135974 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL - The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders. | 2022-05-05 |
20220135975 | INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE - The subject invention provides methods of treating neurological disease or disorder, such as brain injuries, such as stroke, traumatic brain injury (TBI), or other ischemic events that cause brain injury by inhibiting or down-regulating Let-7i activity or function. The disclosed methods may have the potential to extend the “window of opportunity” for treatment of such injuries and enhance the effectiveness of existing therapeutics. | 2022-05-05 |
20220135976 | METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 - The present disclosure relates methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species | 2022-05-05 |
20220135977 | NUCLEIC ACID APTAMER FOR INFLUENZA VIRUS AND DETECTION OF INFLUENZA VIRUS - A nucleic acid aptamer having binding affinity to A/H1N1pdm09 influenza virus, agents comprising the aptamer, and methods using the aptamer are provided. | 2022-05-05 |
20220135978 | ANTI-MIRNA CARRIER CONJUGATED WITH A PEPTIDE BINDING TO A CANCER CELL SURFACE PROTEIN AND USE THEREOF - The present disclosure relates to an anti-miRNA delivery system, and more specifically, relates to a technique of using a cancer-targeting anti-miRNA delivery system including porous silicon nanoparticles containing anti-miRNA to which a cancer cell surface protein-binding peptide is conjugated, for use in treating cancer. As a result of intensive studies in order to use and apply anti-miR-21 oligonucleotides to the treatment of ovarian cancer, the present inventors confirmed for the first time that when porous silicon nanoparticles containing an anti-miRNA-21 oligonucleotide to which a specific cancer cell surface protein-binding peptide is conjugated are applied, apoptosis is induced in an ovarian cancer cell line and cell viability is reduced, thus, an anti-miRNA delivery system, which is the aforementioned conjugate, is expected to be usefully used as a platform for treating various cancers, especially for treating ovarian cancer. | 2022-05-05 |
20220135979 | DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA - Methods for classifying, identifying and monitoring of a medulloblastoma tumor in a subject are provided, based on lincRNA expression in the tumor and/or in a biological sample of the subject. Compositions and methods for treating medulloblastoma using inhibitors of the specific lincRNAs disclosed herein. Additionally, novel inhibitory nucleic acids targeting the specific lincRNAs are provided. | 2022-05-05 |
20220135980 | IMMUNOSTIMULATORY BACTERIA ENGINEERED TO COLONIZE TUMORS, TUMOR-RESIDENT IMMUNE CELLS, AND THE TUMOR MICROENVIRONMENT - Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin | 2022-05-05 |
20220135981 | TARGETING SENESCENT CELLS - Described herein are methods and compositions for treating a subject having a disease associated with an angiopoietin like-2 (angptl2) positive (angptl2+) senescent cell by administering an agent that induces death of the angptl2+ senescent cell. | 2022-05-05 |
20220135982 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF - The present disclosure relates generally to compositions and methods for treating or ameliorating acute myeloid leukemia in a subject in need thereof. In particular, the present disclosure provides a method comprising administering to a subject a therapeutically effective amount of at least one agent that suppresses Trim28 activity. | 2022-05-05 |
20220135983 | PREVENTION OR TREATMENT OF FIBROTIC DISEASE - A modality for preventing or treating fibrotic diseases by identifying a marker protein for myofibroblasts is provided. | 2022-05-05 |
20220135984 | MICROBIOME MODULATION OF A HOST BY DELIVERY OF DNA PAYLOADS WITH MINIMIZED SPREAD - The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding said nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering said nucleic acid of interest. | 2022-05-05 |
20220135985 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION - The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system. | 2022-05-05 |
20220135986 | PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION - The invention relates to | 2022-05-05 |
20220135987 | CUTIBACTERIUM ACNES RECOMBINANT PHAGES, METHOD OF PRODUCTION AND USES THEREOF - The invention relates to | 2022-05-05 |
20220135988 | CONSTRUCTION OF FULLY HUMAN ANTIBODY YEAST DISPLAY TECHNIQUE - The present disclosure application relates to a construction method of a yeast display library (YSD), specifically to a construct for a yeast display library, an expression vector, a host cell and a construction method and use thereof. The yeast display library provided by the present application has high transformation efficiency and rich diversity. | 2022-05-05 |
20220135989 | FERMENTATIVE GLYCEROL-FREE ETHANOL PRODUCTION - The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD | 2022-05-05 |
20220135990 | METHODS OF SUGARCANE TRANSFORMATION USING MORPHOGENES - Aspects of the present disclosure relate to methods and compositions for sugarcane transformation using morphogenic genes. In particular, the present disclosure relates to the use of morphogenic sequences that improve the efficiency of sugarcane cell or tissue transformation and genomic modification. The present disclosure further relates to genetically altered sugarcane cells, tissues, and plants produced using these methods and compositions. | 2022-05-05 |
20220135991 | COMPOSITIONS AND METHODS FOR SITE DIRECTED GENOMIC MODIFICATION - The disclosure provides novel corn, tomato, and soybean U6, U3, U2, U5, and 7SL snRNA promoters which are useful for CRISPR/Cas-mediated targeted gene modifications in plants. The disclosure also provides methods for use for U6, U3, U2, U5, and 7SL promoters in driving expression of sgRNA polynucleotides which function in a CRISPR/Cas system of targeted gene modification in plants. The disclosure also provides methods of genome modification by insertion of blunt-end DNA fragments at a site of genomic cleavage. | 2022-05-05 |
20220135992 | T-DNA VECTORS WITH ENGINEERED 5' SEQUENCES UPSTREAM OF POST-TRANSLATIONAL MODIFICATION ENZYMES AND METHODS OF USE THEREOF - Plant T-DNA expression vectors with engineered 5′ sequences for driving transcription of genes encoding post-translational modification enzymes are provided. Also methods of optimizing expression and glycosylation of recombinant protein produced in plants by utilizing plant T-DNA expression vectors with engineered 5′ sequences for driving transcription of genes encoding post-translational modification enzymes. | 2022-05-05 |
20220135993 | MUTATIONS CONFERRING ACETYL-COA CARBOXYLASE (ACC) INHIBITING HERBICIDE TOLERANCE IN SORGHUM - The invention provides for | 2022-05-05 |
20220135994 | SUPPRESSION OF TARGET GENE EXPRESSION THROUGH GENOME EDITING OF NATIVE MIRNAS - The present invention relates to methods and compositions for reducing or suppressing target gene expression by genome editing of native miRNAs | 2022-05-05 |
20220135995 | PERONOSPORA RESISTANCE IN SPINACIA OLERACEA - The present invention relates to an allele designated alpha-WOLF 27 which confers resistance to at least one | 2022-05-05 |
20220135996 | PERONOSPORA RESISTANCE IN SPINACIA OLERACEA - The present invention relates to an allele designated alpha-WOLF 26 which confers resistance to at least one | 2022-05-05 |
20220135997 | PATHOGEN RESISTANCE IN PLANTS - The present disclosure provides an isolated, recombinant, or synthetic polynucleotide comprising a FIT1 protein, and homologs, fragments, and variations thereof. The disclosure further relates to transgenic plants, plant parts, and plant cells comprising one or more of these polynucleotides, and exhibit resistance or tolerance to a pathogen, such as | 2022-05-05 |
20220135998 | POTYVIRUS RESISTANCE GENES AND METHODS OF USE - Compositions and methods and for enhancing the resistance of plants to plant diseases caused by potyviruses are provided. The compositions comprise nucleic acid molecules encoding resistance (R) gene products and variants thereof and plants, seeds, and plant cells comprising such nucleic acid molecules. The methods for enhancing the resistance of a plant to plant disease caused by a potyvirus comprise introducing a nucleic acid molecule encoding an R gene product into a plant cell. Additionally provided are methods for using the plants in agriculture to limit plant disease. | 2022-05-05 |
20220135999 | COMPOSITIONS AND METHODS FOR CONTROLLING PLANT PESTS - Novel insecticidal proteins isolated from | 2022-05-05 |
20220136000 | OVERCOMING SELF-INCOMPATIBILITY IN DIPLOID PLANTS FOR BREEDING AND PRODUCTION OF HYBRIDS THROUGH MODULATION OF HT - The present invention relates to methods for controlling hybridization in plants and producing hybrid plants. The present invention also relates to nucleic acids encoding amino acid sequences for self-incompatibility (SI) proteins in plants, and the use thereof for the manipulation of SI, including seed production, in plants, particularly of the Solanaceae family. The present invention also relates to kits, compositions, constructs and vectors including such nucleic acids, and related polypeptides, regulatory elements and methods as well as resultant plant varieties developed through the use of self-pollination. | 2022-05-05 |
20220136001 | ARTIFICIAL NUCLEIC ACID MOLECULES - The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element. | 2022-05-05 |
20220136002 | TRANSGENIC MOUSE MODELS SUPPORTING INNATE IMMUNE FUNCTION - Provided herein, in some aspects, is a NOD.Cg-Prkdc | 2022-05-05 |
20220136003 | GENOME-EDITED BIRDS - The present disclosure provides exogenous polynucleotide cassettes for generating chimeric bird cells and chimeric birds. The polynucleotide cassettes can be used to produce conditionally-lethal phenotype in male bird embryos. In one embodiment, the present disclosure provides methods for destroying male chick embryos in-ovo. | 2022-05-05 |
20220136004 | Targeted In Vivo Genome Modification - An in vivo method of modifying a genome of a target cell in a mammalian subject is described. The method includes administering an effective amount of a transducer cell to the subject, where the transducer cell includes a regulated viral vector delivery system (RVVDS) for producing and releasing viral transduction particles (VTPs) when the transducer cell is exposed to inducing conditions, and each VTP comprises a nucleic acid encoding a genome modification system (GMS) comprising a genome modification protein and one or more elements that regulate expression or activity of the genome modification protein in a mammalian cell. | 2022-05-05 |
20220136005 | ONE-STEP GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY VIA GENE REPLACEMENT AND ANTI-INFLAMMATION - In one embodiment, the invention provides a dual-cassette gene vehicle comprising cassettes for expression of both a mini-dystrophin gene and NF-κB/p65-shRNA gene in cardiac muscle tissue and skeletal muscle tissue, which is an adeno-associated viral (AAV) vector, wherein the mini-dystrophin gene is operably linked to a construct comprising a muscle-specific first promoter and a modified Mcken (MCK) enhancer and wherein the NF-κB/p65-shRNA gene is under the control of a second promoter. Also are provided pharmaceutical compositions comprising such gene vehicles and a method for ameliorating Duchenne muscular dystrophy (DMD) employing such gene delivery vehicles and pharmaceutical compositions. | 2022-05-05 |
20220136006 | RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME - IPEX (Immune dysregulation Polyendocinopathy X linked) syndrome is a primary immunodeficience caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ΔLNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional EFS-PGK promoter that showed remarkable efficiency. | 2022-05-05 |
20220136007 | OPTIMIZED LENTIVIRAL VECTOR COMPROMISING MINIMAL ENHANCER ELEMENTS FOR STEM CELL GENE THERAPY OF HEMOGLOBINOPATHIES - In certain embodiments a lentiviral vector having optimized reduced size LCR with improved enhancer activity is provided. In certain embodiments direct treatment of a subject by direct introduction of the vector(s) described herein is contemplated. The lentiviral compositions may be formulated for delivery by any available route including, but not limited to parenteral (e.g., intravenous), intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, rectal, and vaginal. | 2022-05-05 |
20220136008 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATMENT OF GRN-ASSOCIATED ADULT-ONSET NEURODEGENERATION - A recombinant AAV (rAAV) suitable for use in treating adult onset neurodegeneration caused by granulin (GRN) haploinsufficiency, such as progranulin (PGRN)—related frontotemporal dementia (FTD), is provided. The rAAV comprises (a) an adeno-associated virus 1 capsid, and (b) a vector genome packaged in the AAV capsid, said vector genome comprising AAV inverted terminal repeats, a coding sequence for human progranulin, and regulatory sequences which direct expression of the progranulin. Also provided are a method for treating a human patient with PGRN-FTD and other adult onset neurodegeneration caused by granulin (GRN) haploinsufficiencies, comprising delivering to the central nervous system (CNS) a recombinant adeno-associated virus (rAAV) having an adeno-associated virus 1 (AAV1) capsid, said rAAV further comprising a vector genome packaged in the AAV capsid, said vector genome comprising AAV inverted terminal repeats, a coding sequence for human progranulin, and regulatory sequences which direct expression of the progranulin. | 2022-05-05 |
20220136009 | COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATION - Provided herein are engineered transcription factors for selective upregulation of SCN1a and uses thereof for treating diseases and disorders, such as, Dravet syndrome. Also provided are microRNA binding sites and uses thereof for selective expression in parvalbumin neurons. | 2022-05-05 |
20220136010 | METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTOR - Disclosed herein are methods and compositions comprising an adeno-associated virus 2.5 (AAV2.5) capsid protein, comprising one or more amino acids substitutions, (e.g., which does not contain a substitution at the position corresponding to amino acid 267 of AAV2.5, or does not contain a serine at the position corresponding to amino acid 267 of AAV2.5) wherein the substitutions introduce a new glycan binding site into the AAV capsid protein. | 2022-05-05 |
20220136011 | TELOMERASE-CONTAINING EXOSOMES FOR TREATMENT OF DISEASES ASSOCIATED WITH AGING AND AGE-RELATED ORGAN DYSFUNCTION - Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that comprise a therapeutic anti-aging agent. Also provided are methods of using such compositions to treat a patient having an age-associated disorder. In particular, exosomes comprising a telomerase-encoding RNA are provided along with methods of their use in treating age-associated disorders. | 2022-05-05 |
20220136012 | NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE - The invention features nucleobase editors and multi-effector nucleobase editors having an improved editing profile with minimal off-target deamination, compositions comprising such editors, and methods of using the same to generate modifications in target nucleobase sequences. | 2022-05-05 |
20220136013 | DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF STAT1 - RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ NOs 1-37365 and compositions, methods, and uses thereof. | 2022-05-05 |
20220136014 | CRISPR SYSTEMS WITH ENGINEERED DUAL GUIDE NUCLEIC ACIDS - The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system. | 2022-05-05 |
20220136015 | METHOD FOR PRODUCING OXYGEN ADDUCT OF SESQUITERPENE,COMPOUND AND COMPOSITION - A method for producing an oxygen adduct of sesquiterpene, comprising: a step of providing a system comprising an iron reduction unit; a step of adding a trivalent iron compound to the system; and an oxygen addition step of performing oxygen addition to sesquiterpene in the system comprising the iron reduction unit and the trivalent iron compound is a novel method that can efficiently produce an oxygen adduct of sesquiterpene. | 2022-05-05 |
20220136016 | MODIFIED CHLORAMPHENICOL ACETYLTRANSFERASE AND BIOSYNTHESIS METHOD OF MAKING ESTERS USING SAME - A modified chloramphenicol acetyltransferase comprising a tyrosine residue 20 having a phenylalanine (Y20F) mutation, a microorganism harboring the modified chloramphenicol acetyltransferase, and a method of producing ester by feeding the microorganism are disclosed. The method includes providing the microorganism harboring a modified chloramphenicol acetyltransferase in an environment suitable for the microorganism to produce an ester and feeding the microorganism (i) a sugar or a cellulose, and (ii) an alcohol and/or a carboxylic acid. | 2022-05-05 |
20220136017 | RECOMBINANT ALGAE HAVING HIGH LIPID PRODUCTIVITY - The invention provides recombinant algal mutants that have a genetic modification to a gene or nucleic acid sequence encoding a WD40 repeat containing protein or domain. The genetic modification of one or more nucleic acid sequences encoding a WD40 repeat containing protein or domain results in a mutant organism with increased lipid productivity and/or higher biomass productivity (as measured by total organic carbon). The genetic modification can be a gene attenuation or functional deletion. The lipid products of these mutants can be utilized as biofuels or for other specialty chemical products. Methods of making and using the recombinant algal mutants and methods of producing lipids are also disclosed. | 2022-05-05 |
20220136018 | SEMI-BIOSYNTHETIC PRODUCTION OF FATTY ALCOHOLS AND FATTY ALDEHYDES - The present application relates to methods of producing one or more fatty alcohols and/or one or more fatty aldehydes from one or more unsaturated lipid moieties by combining the obtainment or production of the one or more unsaturated lipid moieties from a biological source with conversion by non-biological means of the one or more unsaturated lipid moieties to one or more fatty alcohols and/or one or more fatty aldehydes. The present application also relates to recombinant microorganisms having a biosynthesis pathway for the production of one or more unsaturated lipid moieties. The one or more fatty alcohols can further be chemically converted to one or more corresponding fatty acetates. The one or more fatty alcohols, one or more fatty aldehydes and/or one or more fatty acetates produced by the methods described herein may be one or more insect pheromones, one or more fragrances, one or more flavoring agents, or one or more polymer intermediates. | 2022-05-05 |
20220136019 | EPIGENETIC MODIFICATION OF FUNGI AND USES THEREOF - Described herein are methods of epigenetic modification of fungi and uses thereof. Also described herein are compounds that can have antileishmanial activity and formulations thereof. Also described herein are methods of treating leishmanial infection in a subject that include the step of administering a compound or formulation thereof described herein to the subject. | 2022-05-05 |
20220136020 | Methods for purifying bacterial polysaccharides - The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides. | 2022-05-05 |
20220136021 | SPATIALLY ADDRESSABLE CONTROL OF POLYMERASE ACTIVITY - Multiple polynucleotides having different, arbitrary sequences are synthesized on the surface of an array by spatial control of polymerase activity. The polymerase is a template-independent polymerase such as terminal deoxynucleotidyl transferase (TdT). Spatial control of polymerase activity is implemented by localized changes in redox-pH conditions. A single species of nucleotide is added and incorporated on growing polynucleotide strands at locations on the array where the polymerase is active. A washing step removes the polymerase and free nucleotides. This process may be repeated multiple times changing both the location of polymerase activity and the species of nucleotide thereby synthesizing different polynucleotides in parallel on the surface of the array. Polymerase activity may be regulated by removing a blocking group attached to a His-tag sequence on the polymerase, a change in pH, or release of encapsulated inhibitors. | 2022-05-05 |
20220136022 | Large Scale Synthesis of Messenger RNA - The present invention provides, among other things, methods for large-scale production of a composition comprising full-length messenger RNA product that is substantially free of double-stranded RNA, and compositions produced using such methods and uses thereof. The present invention is based, in part, on the surprising discovery that mRNA product produced by in vitro transcription using an SP6 RNA polymerase is substantially free of double-stranded RNA. In one aspect, the present invention provides methods of generating large-scale mRNA product for mRNA therapy without need for a chromatography step. | 2022-05-05 |
20220136023 | PRACTICAL ENZYMATIC SYNTHESIS OF 3',3'-CGAMP - In an enzymatic synthesis of 3′,3′-cGAMP, other types of cyclic dinucleotides, c-di-GMP and c-di-AMP, are produced as by-products. One problem to be solved in order to establish a practical method for enzymatic synthesis of 3′,3′-cGAMP is suppression of production of these other types of cyclic dinucleotides during the synthesis. As a result of intensive studies, the inventors of the present invention found a variation of 3′,3′-cGAMP synthase by which the production of c-di-GMP and c-di-AMP is suppressed, and established a 3′,3′-cGAMP enzymatic synthesis system using this variation of the enzyme to complete the present invention. This enzyme brings about significantly reduced production of c-di-GMP and c-di-AMP, compared to the wild-type 3′,3′-cGAMP synthase. Accordingly, a production method using this enzyme makes it possible to reduce the production of other types of cyclic dinucleotides in comparison to conventional enzymatic synthesis methods, and efficiently synthesize 3′,3′-cGAMP. | 2022-05-05 |
20220136024 | PROTECTING GROUP CHEMISTRY FOR CLEAN, REDUCTANT-FREE DYEING - The present disclosure relates to the biosynthesis of indigoid dye precursors and their conversion to indigoid dyes. Specifically, the present disclosure relates to methods of using polypeptides to produce indigoid dye precursors from indole feed compounds, and the use of the indigoid dye precursors to produce indigoid dyes. | 2022-05-05 |
20220136025 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES - The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein. | 2022-05-05 |
20220136026 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS - The present invention relates to methods of modulating the mannose content of recombinant proteins. | 2022-05-05 |
20220136027 | PROTEIN HYDROLYSATES WITH INCREASED YIELD OF N-TERMINAL AMINO ACID - The present invention related to a method for preparing a protein hydrolysate from a proteinaceous material by contacting the material with a proteolytic enzyme mixture having a proline specific exopeptidase. In particular, the proline specific exopeptidase is an aminopeptidase specific for at the five amino acid N-terminal sequence X-Pro-Gln-Glv-Pro-, where X is any amino acid. The present invention also relates to use of the aminopeptidase with a second exopeptidase and an endopeptidase. | 2022-05-05 |
20220136028 | RECOMBINANT MICROORGANISM HAVING INCREASED ABILITY TO PRODUCE HYDROPHOBIC MATERIAL AND CELL-MEMBRANE ENGINEERING METHOD FOR PREPARATION THEREOF - Disclosed are a recombinant microorganism for producing a hydrophobic material, which is subjected to cell-membrane engineering in order to be imparted with at least one characteristic among an increase in a cell-membrane area, an increase in formation and secretion of an outer membrane vesicle, and an increase in formation of an inner membrane vesicle, and a cell-membrane engineering method for preparation thereof, whereby an insoluble hydrophobic material can be produced with high efficiency, the recombinant microorganism for high-efficiency production of carotenoids or violacein analogues is useful for producing natural pigments, antioxidants, antibiotics, cosmetic additives, anticancer agents, food additives, or nutritional supplements, and the natural pigment production technology developed herein achieves a great increase in production ability. Therefore, the present invention is effective at preparing a recombinant strain for efficient production of a variety of industrially and medically useful metabolites and at establishing an efficient preparation method. | 2022-05-05 |
20220136029 | BIOTECHNOLOGICAL OPTIMIZATION OF MICROORGANISMS FOR THE 1,2-DEHYDROGENATION OF STEROIDS - The present invention concerns a genetically modified bacterium and to its industrial application, in particular in the 1,2-dehydrogenation of steroids. | 2022-05-05 |